Estados Unidos - inglés - NLM (National Library of Medicine)

lake erie medical dba quality care products llc - buprenorphine (unii: 40d3scr4gz) (buprenorphine - unii:40d3scr4gz) - buprenorphine transdermal system is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. limitations of use buprenorphine transdermal system is contraindicated in patients with: risk summary prolonged use of opioid analgesics during pregnancy may cause neonatal opioid withdrawal syndrome [see warnings and precautions (5.3)]. available data with buprenorphine transdermal system in pregnant women are insufficient to inform a drug-associated risk for major birth defects and miscarriage. in animal reproduction studies, buprenorphine caused an increase in the number of stillborn offspring, reduced litter size, and reduced offspring growth in rats at maternal exposure levels that were approximately 10 times that of human subjects who received one buprenorphine transdermal system 20 mcg/hour, the maximum recommended human dose (mrhd) [see data]. based on animal data, advise pregnant women of the

Australia - inglés - APVMA (Australian Pesticides and Veterinary Medicines Authority)

zoetis australia pty ltd - buprenorphine present as buprenorphine hydrochloride - parenteral liquid/solution/suspension - buprenorphine present as buprenorphine hydrochloride active active 0.3 mg/ml - anaesthetics/analgesics

Canadá - inglés - Health Canada

bard pharmaceuticals (1990) inc - buprenorphine - patch - 5mcg - buprenorphine 5mcg - opiate partial agonists

Canadá - inglés - Health Canada

bard pharmaceuticals (1990) inc - buprenorphine - patch - 10mcg - buprenorphine 10mcg - opiate partial agonists

Canadá - inglés - Health Canada

bard pharmaceuticals (1990) inc - buprenorphine - patch - 15mcg - buprenorphine 15mcg - opiate partial agonists

Canadá - inglés - Health Canada

bard pharmaceuticals (1990) inc - buprenorphine - patch - 20mcg - buprenorphine 20mcg - opiate partial agonists

Estados Unidos - inglés - NLM (National Library of Medicine)

aidarex pharmaceuticals llc - buprenorphine hydrochloride (unii: 56w8mw3en1) (buprenorphine - unii:40d3scr4gz) - buprenorphine 8 mg - buprenorphine sublingual tablets is indicated for the treatment of opioid dependence and is preferred for induction. buprenorphine sublingual tablets should be used as part of a complete treatment plan to include counseling and psychosocial support. under the drug addiction treatment act (data) codified at 21 u.s.c. 823(g), prescription use of this product in the treatment of opioid dependence is limited to physicians who meet certain qualifying requirements, and who have notified the secretary of health and human services (hhs) of their intent to prescribe this product for the treatment of opioid dependence and have been assigned a unique identification number that must be included on every prescription. buprenorphine sublingual tablets should not be administered to patients who have been shown to be hypersensitive to buprenorphine, as serious adverse reactions, including anaphylactic shock, have been reported. [see warnings and precautions (5.8

Estados Unidos - inglés - NLM (National Library of Medicine)

contract pharmacy services-pa - buprenorphine hydrochloride (unii: 56w8mw3en1) (buprenorphine - unii:40d3scr4gz) - buprenorphine 2 mg - buprenorphine sublingual tablets is indicated for the treatment of opioid dependence and is preferred for induction. buprenorphine sublingual tablets should be used as part of a complete treatment plan to include counseling and psychosocial support. under the drug addiction treatment act (data) codified at 21 u.s.c. 823(g), prescription use of this product in the treatment of opioid dependence is limited to physicians who meet certain qualifying requirements, and who have notified the secretary of health and human services (hhs) of their intent to prescribe this product for the treatment of opioid dependence and have been assigned a unique identification number that must be included on every prescription. buprenorphine sublingual tablets should not be administered to patients who have been shown to be hypersensitive to buprenorphine, as serious adverse reactions, including anaphylactic shock, have been reported. [see warnings and precautions

Estados Unidos - inglés - NLM (National Library of Medicine)

indivior inc. - buprenorphine hydrochloride (unii: 56w8mw3en1) (buprenorphine - unii:40d3scr4gz) - buprenorphine 0.3 mg in 1 ml - buprenex is indicated for the management of pain severe enough to require an opioid analgesic and for which alternate treatments are inadequate. because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [see warnings: addiction, abuse, and misuse] reserve buprenex for use in patients for whom alternative treatment options [e.g., non-opioid analgesics or opioid combination products]: - have not been tolerated, or are not expected to be tolerated, - have not provided adequate analgesia, or are not expected to provide adequate analgesia. buprenex is contraindicated in patients with: - significant respiratory depression [see warnings]. - acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment [see warnings]. - known or suspected gastrointestinal obstruction, including paralytic ileus [see warnings]. - hypersensitivity to buprenorphine (e.g. anaphylaxis) or any other ingredient in buprenex [see warnings]. buprenex contains buprenor

Estados Unidos - inglés - NLM (National Library of Medicine)

bryant ranch prepack - buprenorphine hydrochloride (unii: 56w8mw3en1) (buprenorphine - unii:40d3scr4gz) - buprenorphine hydrochloride 8 mg - suboxone and subutex are indicated for the treatment of opioid dependence. suboxone and subutex should not be administered to patients who have been shown to be hypersensitive to buprenorphine, and suboxone should not be administered to patients who have been shown to be hypersensitive to naloxone. suboxone and subutex are controlled as schedule iii narcotics under the controlled substances act. buprenorphine is a partial agonist at the mu-opioid receptor and chronic administration produces dependence of the opioid type, characterized by moderate withdrawal upon abrupt discontinuation or rapid taper. the withdrawal syndrome is milder than seen with full agonists, and may be delayed in onset (see warnings)   neonatal withdrawal has been reported in the infants of women treated with subutex during pregnancy (see precautions)  suboxone contains naloxone and if misused parenterally, is highly likely to produce marked and intense withdrawal symptoms in subjects dependent on other opioid agonists.